RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Swedish Orphan Biovitrum AB (publ) Stock

Swedish Orphan Biovitrum AB (publ) Revenue 2025

Swedish Orphan Biovitrum AB (publ) Revenue

28.9 B SEK

Ticker

SOBI.ST

ISIN

SE0000872095

WKN

A0LA5K

In 2025, Swedish Orphan Biovitrum AB (publ)'s sales reached 28.9 B SEK, a 11.05% difference from the 26.03 B SEK sales recorded in the previous year.

The Swedish Orphan Biovitrum AB (publ) Revenue history

YEARREVENUE (B SEK)GROSS MARGIN (%)
2030e43.3646,84
2029e41.5848,84
2028e38.6652,53
2027e36.5455,58
2026e32.3362,82
2025e28.970,27
202426.0378,03
202322.1277,62
202218.7976,51
202115.5377,56
202015.2678,87
201914.2576,59
20189.1473,57
20176.5171,52
20165.270,14
20153.2362,17
20142.6159,37
20132.1858,99
20121.9254,10
20111.9151,00
20101.9164,04
20091.371,03
20081.1476,79
20071.2672,25
20061.275,54
20050.9471,10

Swedish Orphan Biovitrum AB (publ) Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Swedish Orphan Biovitrum AB (publ), a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Swedish Orphan Biovitrum AB (publ) from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Swedish Orphan Biovitrum AB (publ)’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Swedish Orphan Biovitrum AB (publ). Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Swedish Orphan Biovitrum AB (publ)’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Swedish Orphan Biovitrum AB (publ)’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Swedish Orphan Biovitrum AB (publ)’s growth potential.

Swedish Orphan Biovitrum AB (publ) Revenue, EBIT and net profit per share

DateSwedish Orphan Biovitrum AB (publ) RevenueSwedish Orphan Biovitrum AB (publ) EBITSwedish Orphan Biovitrum AB (publ) Net Income
2030e43.36 B undefined0 undefined9.53 B undefined
2029e41.58 B undefined10.96 B undefined9.24 B undefined
2028e38.66 B undefined9.99 B undefined8.59 B undefined
2027e36.54 B undefined11.19 B undefined8.34 B undefined
2026e32.33 B undefined9.46 B undefined6.77 B undefined
2025e28.9 B undefined7.15 B undefined5.01 B undefined
202426.03 B undefined5.82 B undefined3.89 B undefined
202322.12 B undefined4.68 B undefined2.41 B undefined
202218.79 B undefined4.52 B undefined2.64 B undefined
202115.53 B undefined3.79 B undefined2.68 B undefined
202015.26 B undefined4.46 B undefined3.25 B undefined
201914.25 B undefined4.5 B undefined3.3 B undefined
20189.14 B undefined3.13 B undefined2.42 B undefined
20176.51 B undefined1.65 B undefined1.15 B undefined
20165.2 B undefined1.13 B undefined801 M undefined
20153.23 B undefined148.85 M undefined64.91 M undefined
20142.61 B undefined-328.45 M undefined-267.83 M undefined
20132.18 B undefined-70 M undefined-93 M undefined
20121.92 B undefined-17.5 M undefined-100.9 M undefined
20111.91 B undefined-240.1 M undefined17.9 M undefined
20101.91 B undefined77.4 M undefined-104.5 M undefined
20091.3 B undefined48.3 M undefined32.4 M undefined
20081.14 B undefined-38.9 M undefined-335.4 M undefined
20071.26 B undefined55.1 M undefined79 M undefined
20061.2 B undefined54.6 M undefined92.7 M undefined
2005936.6 M undefined22.1 M undefined261.6 M undefined

Swedish Orphan Biovitrum AB (publ) stock margins

The Swedish Orphan Biovitrum AB (publ) margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Swedish Orphan Biovitrum AB (publ). The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Swedish Orphan Biovitrum AB (publ).

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Swedish Orphan Biovitrum AB (publ)'s sales revenue. A higher gross margin percentage indicates that the Swedish Orphan Biovitrum AB (publ) retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Swedish Orphan Biovitrum AB (publ)'s earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Swedish Orphan Biovitrum AB (publ)'s total revenue generated. When comparing the revenue margin year over year, investors can gauge the Swedish Orphan Biovitrum AB (publ)'s growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Swedish Orphan Biovitrum AB (publ). Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Swedish Orphan Biovitrum AB (publ)'s financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Swedish Orphan Biovitrum AB (publ) Margin History

Swedish Orphan Biovitrum AB (publ) Gross marginSwedish Orphan Biovitrum AB (publ) Profit marginSwedish Orphan Biovitrum AB (publ) EBIT marginSwedish Orphan Biovitrum AB (publ) Profit margin
2030e78.03 %0 %21.97 %
2029e78.03 %26.35 %22.23 %
2028e78.03 %25.83 %22.22 %
2027e78.03 %30.63 %22.83 %
2026e78.03 %29.26 %20.92 %
2025e78.03 %24.72 %17.34 %
202478.03 %22.37 %14.93 %
202377.62 %21.14 %10.89 %
202276.51 %24.06 %14.04 %
202177.56 %24.39 %17.25 %
202078.87 %29.24 %21.26 %
201976.59 %31.58 %23.19 %
201873.57 %34.23 %26.46 %
201771.52 %25.39 %17.64 %
201670.14 %21.77 %15.39 %
201562.17 %4.61 %2.01 %
201459.37 %-12.6 %-10.27 %
201358.99 %-3.22 %-4.27 %
201254.1 %-0.91 %-5.25 %
201151 %-12.57 %0.94 %
201064.04 %4.06 %-5.48 %
200971.03 %3.72 %2.5 %
200876.79 %-3.41 %-29.41 %
200772.25 %4.39 %6.29 %
200675.54 %4.55 %7.72 %
200571.1 %2.36 %27.93 %

Swedish Orphan Biovitrum AB (publ) Aktienanalyse

What does Swedish Orphan Biovitrum AB (publ) do?

Swedish Orphan Biovitrum AB (Sobi) is a Swedish biotechnology company specializing in rare diseases. It was founded in 1986 as Swedish Orphan International and renamed Swedish Orphan Biovitrum AB (Sobi) in 2007. Sobi is headquartered in Stockholm and is listed on NASDAQ OMX Stockholm. Its business model focuses on developing and marketing therapies for rare diseases with limited treatment options. Sobi operates in Europe, the Middle East, North Africa, and North America, collaborating closely with patient organizations and medical professionals to raise awareness of rare diseases and provide patients with access to important therapies. The company is divided into three business areas: Hemophilia, Inflammatory Diseases, and Genetic Diseases. Sobi offers medications for bleeding disorders, inflammatory diseases, and lysosomal storage diseases, among others. Some of its key products include Elocta and Alprolix for Hemophilia A and B, Kineret for autoinflammatory diseases, Synagis for respiratory syncytial virus (RSV) infections in children, Vimizim for mucopolysaccharidosis type IVA, and Orfadin for hereditary tyrosinemia type 1. In conclusion, Sobi is a leading biotechnology company dedicated to developing and marketing therapies for rare diseases, with a wide range of products in its portfolio. It collaborates with patient organizations and strives to improve the quality of life for patients with rare diseases. Swedish Orphan Biovitrum AB (publ) ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Swedish Orphan Biovitrum AB (publ)'s Sales Figures

The sales figures of Swedish Orphan Biovitrum AB (publ) originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Swedish Orphan Biovitrum AB (publ)’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Swedish Orphan Biovitrum AB (publ)'s sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Swedish Orphan Biovitrum AB (publ)’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Swedish Orphan Biovitrum AB (publ) stock

How much revenue did Swedish Orphan Biovitrum AB (publ) generate this year?

Swedish Orphan Biovitrum AB (publ) has achieved a revenue of 28.9 B SEK this year.

How much was the turnover of the company Swedish Orphan Biovitrum AB (publ) compared to the previous year?

The revenue of Swedish Orphan Biovitrum AB (publ) has increased by 11.05% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Swedish Orphan Biovitrum AB (publ)?

The revenue of Swedish Orphan Biovitrum AB (publ) is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Swedish Orphan Biovitrum AB (publ) measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Swedish Orphan Biovitrum AB (publ) so important for investors?

The revenue of Swedish Orphan Biovitrum AB (publ) is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Swedish Orphan Biovitrum AB (publ) pay?

Over the past 12 months, Swedish Orphan Biovitrum AB (publ) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Swedish Orphan Biovitrum AB (publ) is expected to pay a dividend of 0 SEK.

What is the dividend yield of Swedish Orphan Biovitrum AB (publ)?

The current dividend yield of Swedish Orphan Biovitrum AB (publ) is .

When does Swedish Orphan Biovitrum AB (publ) pay dividends?

Swedish Orphan Biovitrum AB (publ) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Swedish Orphan Biovitrum AB (publ)?

Swedish Orphan Biovitrum AB (publ) paid dividends every year for the past 0 years.

What is the dividend of Swedish Orphan Biovitrum AB (publ)?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Swedish Orphan Biovitrum AB (publ) located?

Swedish Orphan Biovitrum AB (publ) is assigned to the 'Health' sector.

Wann musste ich die Aktien von Swedish Orphan Biovitrum AB (publ) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Swedish Orphan Biovitrum AB (publ) from 8/25/2025 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 8/25/2025.

When did Swedish Orphan Biovitrum AB (publ) pay the last dividend?

The last dividend was paid out on 8/25/2025.

What was the dividend of Swedish Orphan Biovitrum AB (publ) in the year 2024?

In the year 2024, Swedish Orphan Biovitrum AB (publ) distributed 0 SEK as dividends.

In which currency does Swedish Orphan Biovitrum AB (publ) pay out the dividend?

The dividends of Swedish Orphan Biovitrum AB (publ) are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Swedish Orphan Biovitrum AB (publ)

Our stock analysis for Swedish Orphan Biovitrum AB (publ) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Swedish Orphan Biovitrum AB (publ) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.